Skip to content

Berberine acts on the Molecular Mechanism of Insulin Resistance in the treatment of Polycystic Ovary Syndrome by Gut microbiota

Berberine acts on the Molecular Mechanism of Insulin Resistance in the treatment of Polycystic Ovary Syndrome by Gut microbiota

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022444
Enrollment
Unknown
Registered
2019-04-11
Start date
2018-08-01
Completion date
Unknown
Last updated
2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome

Interventions

Group 1:Berberine+Drospirenone and Ethinylestradiol Tablets
Group 2:Metformin+Drospirenone and Ethinylestradiol Tablets
Group 3:Drospirenone and Ethinylestradiol Tablets
Group 4:Drospirenone and Ethinylestradiol Tablets
Group 5:No intervention

Sponsors

Guangdong Women's and Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: PCOS-IR and PCOS-NIR patients: 1. Rotterdam diagnostic criteria in line with PCOS; 2. HOMA-IR evaluation, HOMA-IR = fasting insulin (FINS)*fasting blood glucose (FPG)/22.5 = 2.69 for insulin resistance; 3. Women aged 18 to 40 years; 4. Informed consent, voluntary test, and can track observers. Normal population: (selected from our medical examination center): 1. A normal menstrual cycle has been established, and regular menstruation; 2. Healthy women aged 18 and 40 years; 3. Informed consent, voluntary test, and follow-up observers.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Combined with cardiovascular diseases, liver and kidney and hematopoietic system and other serious primary diseases, mental patients; 3. Combined with malignant tumors, adrenal diseases or other diseases leading to organ failure; 4. Patients with glucose-6-phosphate deoxygenase (G6PD) deficiency; 5. BMI <18kg / m2; 6. Anyone who has used any hormonal drugs and drugs that have an effect on insulin secretion in the past 3 months; 7. Those who are allergic to berberine, who are suspected or have a history of alcohol or drug abuse; 8. People with poor compliance.

Design outcomes

Primary

MeasureTime frame
mF-G score;Acne score;FSH;LH;T;PRL;DHEA-S;SHBG;AND;17a-OHP;OGTT;Insulin release test;TG;TCH;HDL;LDL;Hepatorenal function;gynecologic ultrasonography;Detection of Gut mirobiota 16sRNA in fecal samples;

Secondary

MeasureTime frame
Heihgt;weight;BMI;waistline;hipline;WHR;Menstruation situation;

Countries

China

Contacts

Public ContactLi Li

Guangdong Women's and Children's Hospital

lili-1406@163.com+86 13631446859

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026